<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(3)</volume><submitter>Mass H</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Intra-articular injections (IAI) are commonly used to treat knee pain in persons with knee osteoarthritis (OA). We sought to determine the value of commonly used IAIs in knee OA management.&lt;h4>Methods&lt;/h4>We used the validated Osteoarthritis Policy Model (OAPol) to assess the value of saline, corticosteroid (CS), hyaluronic acid (HA), and platelet-rich plasma (PRP) IAIs in knee OA management. We conducted a meta-analysis of high quality studies to estimate IAI-specific pain reduction. We assumed that repeat CS injections increase the risk of OA progression threefold in the base case. We determined the value of specific IAIs with incremental cost-effectiveness ratios (ICERs). We conducted sensitivity analyses to account for uncertainty in input parameters.&lt;h4>Results&lt;/h4>I</pubmed_abstract><journal>Osteoarthritis and cartilage open</journal><pagination>100641</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12284352</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Intra-articular injections for knee osteoarthritis management: Analysis of cost-effectiveness.</pubmed_title><pmcid>PMC12284352</pmcid><pubmed_authors>Neogi T</pubmed_authors><pubmed_authors>Messier SP</pubmed_authors><pubmed_authors>Losina E</pubmed_authors><pubmed_authors>Jones MH</pubmed_authors><pubmed_authors>Tsai L</pubmed_authors><pubmed_authors>Katz JN</pubmed_authors><pubmed_authors>Collins JE</pubmed_authors><pubmed_authors>Yang C</pubmed_authors><pubmed_authors>Hunter DJ</pubmed_authors><pubmed_authors>Mass H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intra-articular injections for knee osteoarthritis management: Analysis of cost-effectiveness.</name><description>&lt;h4>Objective&lt;/h4>Intra-articular injections (IAI) are commonly used to treat knee pain in persons with knee osteoarthritis (OA). We sought to determine the value of commonly used IAIs in knee OA management.&lt;h4>Methods&lt;/h4>We used the validated Osteoarthritis Policy Model (OAPol) to assess the value of saline, corticosteroid (CS), hyaluronic acid (HA), and platelet-rich plasma (PRP) IAIs in knee OA management. We conducted a meta-analysis of high quality studies to estimate IAI-specific pain reduction. We assumed that repeat CS injections increase the risk of OA progression threefold in the base case. We determined the value of specific IAIs with incremental cost-effectiveness ratios (ICERs). We conducted sensitivity analyses to account for uncertainty in input parameters.&lt;h4>Results&lt;/h4>I</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-03-16T04:44:17.58Z</modification><creation>2025-08-15T03:06:15.27Z</creation></dates><accession>S-EPMC12284352</accession><cross_references><pubmed>40703537</pubmed><doi>10.1016/j.ocarto.2025.100641</doi></cross_references></HashMap>